Genprex GNPX Stock News

Genprex Inc (NASDAQ: GNPX) is a stock that’s been on my radar for some time now. Considering recent developments, my view with regard to the stock has only become more bullish.

Nonetheless, the company issued a press release early this morning, providing an update with regard to its recent achievements. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

GNPX Stock Is One To Watch After Today’s Update

In a press release issued early this morning, Genprex updated investors with regard to its recent achievements. In the release, the company said that the achievements outline the efforts that it is taking to expand its clinical development programs and bring its lead drug candidate, Oncoprex, to market.

In the release, GNPX said that it has published a new timeline on its website, showing all recent achievements. Here are the achievements that were achieved in the second quarter of this year:

  • Positive pre-clinical results were announced at the American Association of Cancer Research meeting. The data came from the MD Anderson Cancer Center Sponsored clinical program surrounding the effects of TUSC2 with pembrolizumab.
  • The company also developed a combination clinical trial design that includes the use of Oncoprex in combination with immunotherapy.
  • In the quarter, the comapny also submitted non-proprietary drug name selections as part of its collaboration with Addison Whitney for its drug nomenclature branding program.
  • GNPX also initiated the manufacturing process with key manufacturing partners that have the ability to scale-up manufacturing as necessary.
  • Finally, the company completed the manufacturing of TUSC2 DNA plasmid. This is expected to support a ramp up in clinical activity.

In a statement, Rodney Varner, Chairman and CEO at GNPX, had the following to offer:

Since Genprex’s IPO last year, we have made significant progress in many areas of the company, including progress toward expansion of our clinical programs and sponsored research, our manufacturing process development and scalability, and the growth of our team to support these initatives.

These accomplishments have set the stage for us to continue on our path of growth and expansion, enabling our efforts to bring our drug candidate to market for lung cancer patients who cannot benefit from today’s therapies.

If You’re Not Paying Attention To Genprex, Now Is The Time To Start

The bottom line here is a simple one. GNPX represents a compelling investment opportunity. While the stock price has been drug down as of late, recent declines are only expanding the opportunity.

The companys efforts, especially with regard to Oncoprex, are likely to pay off in the long run. Moreover, considering the work that the company has done in recent quarters, there’s a strong likelyhood that several catalysts are ahead.

So, if you’re not watching the stock yet, now is the time to put GNPX on your watch list.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Be The Next To Miss The News

Join our free mailing list below to receive real-time alerts!

Subscribe Today!

* indicates required



CNA Finance, parent company to Alpha Stock News, has been paid to cover Genprex news.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.